Clinical trial NCT06922110: An Open-Label Study of Azetukalner in Major Depressive Disorder
Official title: A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE3
Conditions: Major Depressive Disorder
Keywords: Depression
Antidepressant
XEN1101
Azetukalner
Lead sponsor: Xenon Pharmaceuticals Inc.
Sponsor class: INDUSTRY
First posted: 2025-04-10
Enrollment: 460
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).


Eligibility criteria: Inclusion Criteria:

* Participant successfully completed the treatment period of an antecedent azetukalner Phase 3 study in MDD.
* Participant provides written informed consent to participate in the study, is able to understand the procedures and study requirements, and agrees to abide by them.
* Participant is willing to comply with the contraception requirements.
* Male participants must agree not to donate sperm until 3 months after the last dose of study drug. Female participants must agree not to donate ova until 3 months after the last dose of study drug.

Exclusion Criteria:

* Participant met any of the withdrawal criteria, or discontinued study drug early, or was terminated early from an antecedent study.
* Participant had any protocol deviations in an antecedent azetukalner study that, in the opinion of the investigator, would preclude participation in this study.
* Participant is unable to comply with study procedures or is inappropriate for the study, as judged by the investigator.
* Participant has any medical condition, personal circumstance, or ongoing AE (from an antecedent study) that, in the opinion of the investigator, exposes the participant to unacceptable risk by participating in the study or prevents adherence to the protocol.
* Female participant who is pregnant, breastfeeding, or planning to become pregnant within 3 months after the last dose of study drug.
* Participant is planning to enter a clinical study with a different investigational drug or planning to use any experimental device for treatment of any medical condition during the study or within 28 days after completion of this study.
* Participant is judged to have a significant risk for self-harm or suicidal behavior or is considered to be an imminent danger to themself or others, as determined by the C-SSRS or in the opinion of the investigator.

Primary outcomes:
measure: Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interest
timeFrame: From the start of treatment in the open-label extension study through 8 weeks after the last dose
Secondary outcomes:
measure: Change from baseline in the Hamilton Depression Rating Scale, 17-Item (HAMD-17) total score over time
timeFrame: From baseline through the active extension treatment (Week 52)
measure: Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score over time
timeFrame: From baseline through the active extension treatment (Week 52)
measure: Change in the Clinical Global Impression of Severity (CGI-S) score over time
timeFrame: From baseline through the active extension treatment (Week 52)
measure: Change from baseline in Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) total score, Q-LES-Q-SF medication and life satisfaction and contentment in item scores over time
timeFrame: From baseline through the active extension treatment (Week 52)
measure: Change from baseline in Sheehan Disability Scale (SDS) total score and subscale scores over time
timeFrame: From baseline through the active extension treatment (Week 52)
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Chicago Research Center Inc.
state: Illinois
city: Memphis
country: United States
facility: Clinical Neuroscience Solutions, Inc.
state: Tennessee
Study officials:
References: